Blood Samples to Evaluate Biomarkers of Donor Chimerism

Fred Hutchinson Cancer Center1 site in 1 country80 target enrollmentSeptember 2008

ConditionsLeukemia Hodgkins Disease Non-hodgkins Lymphoma Myelodysplastic Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Leukemia
Sponsor: Fred Hutchinson Cancer Center
Enrollment: 80
Locations: 1
Primary Endpoint: Donor T-cell chimerism
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.

Registry

clinicaltrials.gov

Start Date

September 2008

End Date

February 2012

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fred Hutchinson Cancer Center

Eligibility Criteria

Inclusion Criteria

•Diagnosed with a hematologic disease or malignancy
•Scheduled to receive nonablative conditioning with fludarabine and total body irradiation
•Donor is well-matched by high resolution DNA techniques.
•Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral calcineurin inhibitor.
•Age \>18 years at the time of enrollment.
•Exclusion criteria:
•Diagnosed with an immunodeficiency disorder